Ficlatuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ficlatuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target HGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6446H9954N1718O2026S46
Molar mass 145.41 kg/mol
 NYesY (what is this?)  (verify)

Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]

Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[2]

References[edit]